Company Interview / Imugene transforms the cancer treatment landscape one trial at a time

Imugene CEO Leslie Chong states that the company is making significant strides in cancer immunotherapy treatments, focusing on products designed to activate the immune system against cancer. All current products are being developed in patients, not just at a preclinical stage. According to Chong, the recent Azercell trial has reported an 81% response rate, a notable improvement from prior results and above the benchmark set by currently approved CAR-T therapies for blood cancers. Chong characterises these results as early stage, with a pivotal registration study required as the next step to confirm efficacy.

Imugene (ASX:IMU) is centring its efforts on Azercell, which may enter the market within five years if regulatory dialogue with the FDA progresses as anticipated. Chong highlights Azercell’s potential to address rare lymphomas and blood cancers for patients with unmet medical needs, citing the streamlined approval pathways often available for such indications. The treatment’s off-the-shelf, allogeneic approach allows rapid administration, bypassing some delays associated with existing CAR-T technologies.

On the financial front, Chong explains that a $23 million capital raising supports ongoing clinical trials, with approximately 70% of funds directed to these activities. Cost reductions have been realised through the out-licensing of manufacturing facilities and program prioritisation. Despite a lower share price at $0.38 and a market value of $112 million, Chong emphasises a focus on long-term product development rather than short-term market movements.

*The information contained in this event is general in nature and is not intended as advice. Before acting on information you've seen or heard at this event, you should seek professional financial advice that takes into account your personal circumstances. 

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD